A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Status:
RECRUITING

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

PHASE1

Stemline Therapeutics, Inc.

elacestrant